Head-To-Head Comparison: Northwest Biotherapeutics (NWBO) and The Competition
Head-To-Head Comparison: Northwest Biotherapeutics (NWBO) and The Competition
Northwest Biotherapeutics (OTCMKTS:NWBO – Get Rating) is one of 993 public companies in the "Pharmaceutical preparations" industry, but how does it compare to its competitors? We will compare Northwest Biotherapeutics to similar companies based on the strength of its earnings, valuation, analyst recommendations, institutional ownership, dividends, profitability and risk.
Northwest Biotherapeutics（OTCMKTS: NWBO — 獲取評級）是 “藥物製劑” 行業的993家上市公司之一，但與競爭對手相比如何？我們將根據Northwest Biotherapeutics的收益、估值、分析師建議、機構所有權、股息、盈利能力和風險將其與同類公司進行比較。
Earnings and Valuation
收益和估值
This table compares Northwest Biotherapeutics and its competitors revenue, earnings per share and valuation.
該表比較了Northwest Biotherapeutics及其競爭對手的收入、每股收益和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Northwest Biotherapeutics | $1.68 million | -$105.03 million | -5.20 |
| Northwest Biotherapeutics Competitors | $1.81 billion | $241.52 million | -3.90 |
| 總收入 | 淨收入 | 市盈率 | |
| 西北生物療法 | 168 萬美元 | -1.0503 億美元 | -5.20 |
| 西北生物療法競爭對手 | 18.1 億美元 | 2.4152 億美元 | -3.90 |
Northwest Biotherapeutics' competitors have higher revenue and earnings than Northwest Biotherapeutics. Northwest Biotherapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Northwest Biotherapeutics的競爭對手的收入和收益高於西北生物療法。Northwest Biotherapeutics的交易市盈率低於競爭對手，這表明它目前比業內其他公司更實惠。
Volatility and Risk
波動率和風險
Northwest Biotherapeutics has a beta of -0.07, suggesting that its stock price is 107% less volatile than the S&P 500. Comparatively, Northwest Biotherapeutics' competitors have a beta of 0.91, suggesting that their average stock price is 9% less volatile than the S&P 500.
Northwest Biotherapeutics的beta值爲-0.07，這表明其股價的波動性比標準普爾500指數低107％。相比之下，Northwest Biotherapeutics的競爭對手的beta值爲0.91，這表明他們的平均股價波動性比標準普爾500指數低9％。
Institutional & Insider Ownership
機構和內部所有權
0.2% of Northwest Biotherapeutics shares are owned by institutional investors. Comparatively, 40.7% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 13.9% of Northwest Biotherapeutics shares are owned by company insiders. Comparatively, 15.6% of shares of all "Pharmaceutical preparations" companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Northwest Biotherapeutics的0.2％股份由機構投資者持有。相比之下，所有 “藥物製劑” 公司的40.7％的股份由機構投資者擁有。西北生物治療公司13.9％的股份由公司內部人士擁有。相比之下，所有 “藥物製劑” 公司的15.6％的股份由公司內部人士擁有。強大的機構所有權表明大型基金經理、捐贈基金和對沖基金認爲，從長遠來看，股票的表現將優於市場。
Profitability
盈利能力
This table compares Northwest Biotherapeutics and its competitors' net margins, return on equity and return on assets.
該表比較了Northwest Biotherapeutics及其競爭對手的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Northwest Biotherapeutics | -6,240.76% | -50.86% | -348.36% |
| Northwest Biotherapeutics Competitors | -3,408.19% | -234.46% | -35.34% |
| 淨利潤 | 股本回報率 | 資產回報率 | |
| 西北生物療法 | -6,240.76% | -50.86% | -348.36% |
| 西北生物療法競爭對手 | -3,408.19% | -234.46% | -35.34% |
Analyst Recommendations
分析師建議
This is a summary of recent ratings and target prices for Northwest Biotherapeutics and its competitors, as reported by MarketBeat.com.
據Marketbeat.com報道，這是Northwest Biotherapeutics及其競爭對手最近的評級和目標價格的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Northwest Biotherapeutics | 0 | 0 | 0 | 0 | N/A |
| Northwest Biotherapeutics Competitors | 4253 | 15151 | 41626 | 722 | 2.63 |
| 賣出評級 | 持有評級 | 買入評級 | 強勁的買入評級 | 評分分數 | |
| 西北生物療法 | 0 | 0 | 0 | 0 | 不適用 |
| 西北生物療法競爭對手 | 4253 | 15151 | 41626 | 722 | 2.63 |
As a group, "Pharmaceutical preparations" companies have a potential upside of 106.28%. Given Northwest Biotherapeutics' competitors higher possible upside, analysts plainly believe Northwest Biotherapeutics has less favorable growth aspects than its competitors.
作爲一個整體，“藥物製劑” 公司的潛在上漲空間爲106.28％。鑑於Northwest Biotherapeutics的競爭對手可能有更大的上行空間，分析師顯然認爲，Northwest Biotherapeutics的增長方面
Summary
摘要
Northwest Biotherapeutics competitors beat Northwest Biotherapeutics on 9 of the 10 factors compared.
在比較的10個因素中，西北生物療法的競爭對手在9個因素上擊敗了西北生物治療公司。
About Northwest Biotherapeutics
關於西北生物療法
(Get Rating)
（獲取評級）
Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.
Northwest Biotherapeutics, Inc. 是一家生物技術公司，從事癌症個性化免疫療法的開發。它提供了 dcVax 技術平臺，該平臺使用活化的樹突狀細胞調動患者自身的免疫系統來攻擊他們的癌症。該公司由 Alton L. Boynton 於 1996 年 3 月 18 日創立，總部位於馬里蘭州貝塞斯達。
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收《西北生物療法日報》的新聞和評級 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Northwest Biotherapeutics及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。